Patents Assigned to Tactic Pharma, LLC

Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof

Patent number: 8105602

Abstract: The present invention relates to antibodies, and antigen-binding fragments thereof, specific for urokinase-type plasminogen activator receptor (uPAR) and uses thereof for the treatment or prevention of cancer. In particular, the antibodies of the invention are specific for a particular epitope on uPAR. These antibodies interfere with uPAR signaling. Such antibodies are used in diagnostic and therapeutic methods, particularly against cancer.

Type: Grant

Filed: December 7, 2007

Date of Patent: January 31, 2012

Assignee: Tactic Pharma, LLC

Inventors: Graham Parry, Andrew P. Mazar
Ligands binding the complex of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) that inhibit downstream uPAR interactions: identification and use in diagnosis or therapy

Patent number: 8101726

Abstract: Antibodies or other ligands specific for the binary uPA-uPAR complexes, for ternary complexes comprising uPA-uPAR and for complexes of uPAR and proteins other than uPA such as integrins inhibit the interaction of uPA and uPAR with additional molecules with which the complexed interact. Such antibodies or other ligands are used in diagnostic and therapeutic methods, particularly against cancer.

Type: Grant

Filed: May 25, 2005

Date of Patent: January 24, 2012

Assignee: Tactic Pharma, LLC

Inventors: Graham C. Parry, Andrew P. Mazar

Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof

Ligands binding the complex of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) that inhibit downstream uPAR interactions: identification and use in diagnosis or therapy